Search research articles
Contact Us
Filters
Showing results (1-10 of 126) with videos related to
Page
of 13
Sort By:
Cancer
|
December 30, 2020
Circulating interleukin 6, androgen deprivation therapy, and fatigue in prostate cancer: Is inflammation the link?
Bassel Nazha, Mehmet Asim Bilen
Cancer Treatment and Research Communications
|
December 11, 2020
Immunotherapy in sarcomatoid renal cell carcinoma: A case for optimism
Jacqueline T Brown, Mehmet Asim Bilen
Ebiomedicine
|
September 11, 2019
Management of metastatic renal cell carcinoma: The complexity of choice
Jacqueline T Brown, Mehmet Asim Bilen
Vaccines
|
August 15, 2018
Therapeutic Vaccines for Genitourinary Malignancies
Giselle M A Dutcher, Mehmet Asim Bilen
Kidney Cancer (Clifton, Va.)
|
December 24, 2019
A Review of Papillary Renal Cell Carcinoma and MET Inhibitors
Katherine Emilie Rhoades Smith, Mehmet Asim Bilen
Expert Opinion on Investigational Drugs
|
January 12, 2018
The prospects for combination therapy with capecitabine in the rapidly evolving treatment landscape of renal cell carcinoma
Mehmet Asim Bilen, Jennifer W Carlisle, Guru Sonpavde
Serican Journal of Medicine
|
February 9, 2026
Therapeutic targeting of Aurora Kinase A in advanced prostate cancer
Maroun Bou Zerdan, Mehmet Asim Bilen, Jindan Yu
Clinical Genitourinary Cancer
|
July 7, 2011
Prolonged remission of fulminant castrate-resistant prostate cancer: a case report
Mehmet Asim Bilen, Rosale General, Shi-Ming Tu
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 22, 2023
Combined Programmed Death-Ligand 1 and MET Inhibition: Has Papillary Renal Cell Carcinoma MET Its Match?
Jacqueline T Brown, Bassel Nazha, Mehmet Asim Bilen
Biology
|
April 30, 2021
Inflammatory Markers in Cancer Immunotherapy
Deepak Ravindranathan, Viraj A Master, Mehmet Asim Bilen
Page
of 13
Search research articles
Search
Showing results (1-10 of 126) with videos related to
Sort By:
Page
of 13
Cancer
|
December 30, 2020
Circulating interleukin 6, androgen deprivation therapy, and fatigue in prostate cancer: Is inflammation the link?
Bassel Nazha, Mehmet Asim Bilen
Cancer Treatment and Research Communications
|
December 11, 2020
Immunotherapy in sarcomatoid renal cell carcinoma: A case for optimism
Jacqueline T Brown, Mehmet Asim Bilen
Ebiomedicine
|
September 11, 2019
Management of metastatic renal cell carcinoma: The complexity of choice
Jacqueline T Brown, Mehmet Asim Bilen
Vaccines
|
August 15, 2018
Therapeutic Vaccines for Genitourinary Malignancies
Giselle M A Dutcher, Mehmet Asim Bilen
Kidney Cancer (Clifton, Va.)
|
December 24, 2019
A Review of Papillary Renal Cell Carcinoma and MET Inhibitors
Katherine Emilie Rhoades Smith, Mehmet Asim Bilen
Expert Opinion on Investigational Drugs
|
January 12, 2018
The prospects for combination therapy with capecitabine in the rapidly evolving treatment landscape of renal cell carcinoma
Mehmet Asim Bilen, Jennifer W Carlisle, Guru Sonpavde
Serican Journal of Medicine
|
February 9, 2026
Therapeutic targeting of Aurora Kinase A in advanced prostate cancer
Maroun Bou Zerdan, Mehmet Asim Bilen, Jindan Yu
Clinical Genitourinary Cancer
|
July 7, 2011
Prolonged remission of fulminant castrate-resistant prostate cancer: a case report
Mehmet Asim Bilen, Rosale General, Shi-Ming Tu
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 22, 2023
Combined Programmed Death-Ligand 1 and MET Inhibition: Has Papillary Renal Cell Carcinoma MET Its Match?
Jacqueline T Brown, Bassel Nazha, Mehmet Asim Bilen
Biology
|
April 30, 2021
Inflammatory Markers in Cancer Immunotherapy
Deepak Ravindranathan, Viraj A Master, Mehmet Asim Bilen
Page
of 13